Considerations in sirolimus use in the early and late post-transplant periods (Q37517602)

20 August 2017

1 reference

title

Considerations in sirolimus use in the early and late post-transplant periods (English)

1 reference

20 August 2017

1 reference

Samir J Patel

1

1 reference

20 August 2017

Erin N Elliott

2

1 reference

20 August 2017

Richard J Knight

3

1 reference

20 August 2017

Lillian W Gaber

4

1 reference

20 August 2017

A Osama Gaber

5

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

Expert Opinion on Drug Safety

20 August 2017

published in

1 reference

20 August 2017

volume

8

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

421-434

1 reference

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Benefit-risk assessment of sirolimus in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Steroid withdrawal five days after renal transplantation allows for the prevention of wound-healing complications associated with sirolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Induction sirolimus and delayed graft function after deceased donor kidney transplantation in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Conversion to sirolimus in solid organ transplantation: a Single-Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Proteinuria following a switch from calcineurin inhibitors to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E-Deficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Long-Term Renal Allograft Function on a Tacrolimus-Based, Pred-Free Maintenance Immunosuppression Comparing Sirolimus vs. MMF+

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903037156

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Identifiers

DOI

10.1517/14740330903037156

1 reference

20 August 2017

1 reference